Harald Mauser

This inventor holds 20 USPTO granted patents and 11 published patent applications and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Hoffmann-La Roche Inc., Siena Biotech S.p.a.. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Harald Mauser. Retrieved from https://idiyas.com/inventor/harald-mauser

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 11)

% Patents Active = 20.0

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 6.1

ph-index = 6

Forward Citations = 79(Granted Patents)

Location History:

Schliengen, DE (2009 - 2013)
Birsfelden, CH (2011 - 2014)
Riehen, CH (2014 - 2021)

Company Filing History:

20 out of 5,026

Hoffmann-La Roche Inc.

where one patent can have more than one assignee

Years Active: 2009-2021

Loading Chart...

Areas of Expertise:

Autotaxin Inhibitors

BACE1 Inhibitors

BACE2 Inhibitors

Pyrrole Derivatives

Oxazine Compounds

Piperidine Derivatives

Dihydropyrimidinones

Cyclopentane Derivatives

Amino Oxazine Derivatives

Sulfonamide Derivatives

Proline Derivatives

Vinylogous Acid Derivatives

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10913745 - Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors (2021-02-09),

2. 10669268 - Bicyclic derivatives (2020-06-02),

3. 10633384 - Diazaspirocycloalkane and azaspirocycloalkane (2020-04-28),

4. 10172843 - Piperidine derivatives (2019-01-08),

5. 9493486 - Diazaspirocycloalkane and azaspirocycloalkane (2016-11-15),

6. 9242943 - 1,4 oxazines as BACE1 and/or BACE2 inhibitors (2016-01-26),

7. 8815881 - 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds (2014-08-26),

8. 8748418 - 1,4-oxazepines as BACE1 and/or BACE2 inhibitors (2014-06-10),

9. 8673894 - 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds (2014-03-18),

10. 8524710 - Pyrrolidine derivatives (2013-09-03),

11. 8461160 - Dihydropyrimidinones (2013-06-11),

12. 8389513 - 2-amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides (2013-03-05),

13. 8188079 - 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines (2012-05-29),

14. 8163793 - Proline derivatives (2012-04-24),

15. 8158655 - Sulfonamide derivatives (2012-04-17),

Title: Harald Mauser: A Pioneer in Pharmaceutical Innovations

Introduction

Harald Mauser, based in Riehen, Switzerland, is an esteemed inventor with a notable portfolio of 20 patents. His work primarily focuses on developing innovative pharmaceutical compounds that have the potential to advance medical therapies significantly.

Latest Patents

Among his latest contributions are his patents concerning octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs, which act as autotaxin inhibitors. This invention details novel compounds expressed by a specific general formula, emphasizing their potential applications. Additionally, Mauser has worked on bicyclic derivatives, achieving similar innovations and detailing their compositions and applications in combating health challenges.

Career Highlights

Throughout his career, Mauser has collaborated with prominent companies in the pharmaceutical field, including Hoffmann-La Roche Inc. and Siena Biotech S.p.a. His expertise and innovative strategies have positioned him as a significant contributor to drug development and research.

Collaborations

Mauser's work has been enriched through collaborations with notable figures, including David Banner and Hans Hilpert. These partnerships have facilitated the exchange of ideas and research methodologies, further propelling advancements in medicinal chemistry.

Conclusion

Harald Mauser's dedication to innovation in the pharmaceutical industry has established him as a key figure in drug development. With his extensive patent portfolio and collaborative efforts, he continues to contribute valuable insights and innovations that enhance therapeutic options for various medical conditions.

Profile summary based on public USPTO records.